TORONTO, Ontario and HAIFA, Israel, April 16, 2026 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV:NRX) (OTCQB:NRXBF) (FSE: J90) (“NurExone” or the “Company“), a biopharmaceutical company developing exosome-based regenerative therapies for central nervous system (“CNS“) injuries is pleased to provide a business update and reported financial results for the fourth quarter and financial year ended December 31, 2025. The Company’s lead program, ExoPTEN, is being developed for acute spinal cord injury and optic nerve damage, with additional potential indications including traumatic brain injury and facial nerve injury.
The Company’s audited consolidated financial statements for the fiscal years ended December 31, 2025 and 2024 and accompanying management discussion and analysis can be accessed by visiting the Company’s website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.
2025 Highlights and Significant Milestones
- Advancement of ExoPTEN Therapy: Throughout 2025, the Company continued to refine its preclinical data and address feedback from the U.S. Food and Drug Administration (“FDA“) as it advanced key milestones towards the submission of an Investigational New Drug (“IND“) application for ExoPTEN. NurExone generated additional encouraging preclinical results that strengthened confidence in ExoPTEN’s therapeutic potential, while also advancing work on dosing, manufacturing, and product characterization. These efforts support preparation for regulatory review, clinical development and first-in-human clinical trials.
- Establishment of Exo-Top and U.S. Expansion: On February 4, 2025, the Company established Exo-Top Inc., (“Exo-Top“) a wholly owned U.S. subsidiary in Nevada. This strategic move, together with the acquisition of a proprietary Master Cell Bank (“MCB“), supports the independent production and commercial supply of high-quality naïve exosomes for the Company’s future pipeline.
- Financial Strengthening: During the year ended December 31, 2025, the Company significantly strengthened its capital structure and liquidity position through a series of private placements, warrant exercises, and stock option exercises, generating aggregate gross proceeds of approximately US$5.9 million. These financing activities supported the Company’s ongoing operations and development initiatives. Key transactions included:
- January 2025 Private Placement: On January 21, 2025, the Company completed a non-brokered private placement of 856,996 units at C$0.56 per unit, generating gross proceeds of approximately US$333 thousand (C$480 thousand). Each unit consisted of one Common Share and one Common Share purchase warrant exercisable at C$0.70 for a period of 36 months.
- April 2025 Private Placement: On April 9, 2025, the Company completed a non-brokered private placement of 3,543,238 units at C$0.65 per unit, generating gross proceeds of approximately US$1.6 million (C$2.3 million). Each unit consisted of one Common Share and one warrant exercisable at C$0.85.
- August 2025 Private Placement: On August 20, 2025, the Company completed a non-brokered private placement of 1,258,072 units at C$0.62 per unit, generating gross proceeds of approximately US$568 thousand (C$780 thousand). Each unit consisted of one Common Share and one-half of one warrant exercisable at C$0.80.
- September 2025 Private Placement: On September 11, 2025, the Company completed a non-brokered private placement of 930,376 units at C$0.68 per unit, generating gross proceeds of approximately US$457 thousand (C$633 thousand). Each unit consisted of one Common Share and one-half of one warrant exercisable at C$0.88.
- Warrant Exercises: During 2025, the Company received significant proceeds from warrant exercises, including the full exercise of all outstanding September 2023 and January 2024 warrants following the Company’s acceleration notice, as well as additional exercises throughout the year. In aggregate, warrant exercises generated approximately US$2.95 million (C$4.17 million) in gross proceeds.
These financing activities collectively supported the Company’s continued development and operational activities during the year.
- Company Continuance: On April 22, 2025, the Company completed its continuance from the Province of Alberta to the Province of Ontario, now governed by the Business Corporations Act (Ontario).
- U.S. Commercial and Manufacturing Strategy: Subsequent to year-end, the Company further advanced Exo-Top’s role in its U.S. strategy through an internal sublicensing agreement and a non-binding letter of intent with BioXtek Inc., intended to support U.S. GMP manufacturing, clinical supply, and potential commercialization of naïve exosomes.